Edition:
United Kingdom

People: Accelerate Diagnostics Inc (AXDX.OQ)

AXDX.OQ on NASDAQ Stock Exchange Capital Market

19.08USD
17 Jul 2019
Change (% chg)

$-0.04 (-0.21%)
Prev Close
$19.12
Open
$19.32
Day's High
$19.56
Day's Low
$19.00
Volume
87,451
Avg. Vol
71,975
52-wk High
$24.70
52-wk Low
$10.25

Reichling, Steve 

Mr. Steve Reichling is Chief Financial Officer of Accelerate Diagnostics Inc. since September 10, 2012. Prior to joining the Company, Mr. Reichling served as general manager of Spring Bioscience Corp. a subsidiary of Roche Tissue Diagnostics. From January 2003 to December 2009, Mr. Reichling held various finance, accounting and operations leadership roles at Roche Tissue Diagnostics and Ventana Medical Systems, Inc. including director of finance and operations, manager of business development finance, and head of Internal Audit and Sarbanes Oxley Compliance. From October 2002 to January 2003, Mr. Reichling was an auditor at Ernst & Young LLP. Mr. Reichling received his B.A. in accounting and entrepreneurship from the University of Arizona and is a Certified Public Accountant.

Basic Compensation

Total Annual Compensation, USD 240,000
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 454,800
Fiscal Year Total, USD 694,800

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 30,000 777,750.00
Name Fiscal Year Total

John Patience

161,802

Lawrence Mehren

375,000

Steve Reichling

694,800

Ron Price

871,188

Thomas Brown

767,025

Mark Miller

161,802
As Of  31 Dec 2017